ConductScience.org, home

Paper35637402

Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors.

Zhang H and 26 others. Nat Cancer, 2022. Cited by 49 papers, by iCite.

Cite this record

ConductScience Library. Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors. Papers, record 35637402. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35637402

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors.
PubMed
Journal
Nat Cancer
PubMed
Year
2022
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
49
iCite
Relative citation ratio, by iCite
2.87
iCite
Revised in PubMed
2025-10-31
PubMed

Authors27

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhang HHongru
2Yu PPengfeihttps://orcid.org/0000-0002-3894-5697
3Tomar VSVivek S
4Chen XXiangjie
5Atherton MJMatthew Jhttps://orcid.org/0000-0002-9830-3151
6Lu ZZhen
7Zhang HGHong-Guang
8Li SShifeng
9Ortiz AAngelica
10Gui JJun
11Leu NAN Adrian
12Yan FFangxue
13Blanco AAndres
14Meyer-Ficca MLMirella Lhttps://orcid.org/0000-0002-9949-8157
15Meyer RGRalph G
16Beiting DPDaniel P
17Li JJinyang
18Nunez-Cruz SSelene
19O'Connor RSRoddy S
20Johnson LRLexus R

Source PubMed

See all 27 authorsDownload CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NeoplasmsMajor topic
Poly(ADP-ribose) PolymerasesMajor topic
Receptors, Chimeric AntigenMajor topic
Humans
Immunosuppression Therapy
Immunotherapy, Adoptive
Tumor Microenvironment

Source PubMed

Download CSV of topics

Grants8

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 HD103027NICHD NIH HHSUnited StatesR01HD103027PubMedNIH RePORTER
P01 CA165997NCI NIH HHSUnited StatesP01CA165997PubMedNIH RePORTER
R56 AG069745NIA NIH HHSUnited StatesR56AG069745PubMedNIH RePORTER
R01 CA233790NCI NIH HHSUnited StatesR01CA233790PubMedNIH RePORTER
R01 CA247803NCI NIH HHSUnited StatesR01CA247803PubMedNIH RePORTER
R01 CA240814NCI NIH HHSUnited StatesR01CA240814PubMedNIH RePORTER
R15 HD100970NICHD NIH HHSUnited StatesR15HD100970PubMedNIH RePORTER
K08 CA252619NCI NIH HHSUnited StatesK08CA252619PubMedNIH RePORTER

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in35883000PARP11 interfer(on)es with CAR T cell efficacy.https://conductscience.org/library/papers/35883000

Source PubMed

Download CSV of comments and corrections

References50

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133750922Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion.Nat Rev Cancer2021https://conductscience.org/library/papers/33750922PubMed
230523282Cancer immunoediting and resistance to T cell-based immunotherapy.Nat Rev Clin Oncol2019https://conductscience.org/library/papers/30523282PubMed
317476343Immune surveillance of tumors.J Clin Invest2007https://conductscience.org/library/papers/17476343PubMed
422439926Accessories to the crime: functions of cells recruited to the tumor microenvironment.Cancer Cell2012https://conductscience.org/library/papers/22439926PubMed
525838376T cell exclusion, immune privilege, and the tumor microenvironment.Science2015https://conductscience.org/library/papers/25838376PubMed
626787424Targeting regulatory T cells in tumors.FEBS J2016https://conductscience.org/library/papers/26787424PubMed
728192720Dendritic cells in cancer: the role revisited.Curr Opin Immunol2017https://conductscience.org/library/papers/28192720PubMed
829059149Targeting immunosuppressive adenosine in cancer.Nat Rev Cancer2017https://conductscience.org/library/papers/29059149PubMed
932514148The adenosine pathway in immuno-oncology.Nat Rev Clin Oncol2020https://conductscience.org/library/papers/32514148PubMed
1026598942Combination cancer immunotherapies tailored to the tumour microenvironment.Nat Rev Clin Oncol2016https://conductscience.org/library/papers/26598942PubMed
1125860605Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.Cell2015https://conductscience.org/library/papers/25860605PubMed
1223570388Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy.J Interferon Cytokine Res2013https://conductscience.org/library/papers/23570388PubMed
1326911188Antitumour actions of interferons: implications for cancer therapy.Nat Rev Cancer2016https://conductscience.org/library/papers/26911188PubMed
1426027717Type I interferons in anticancer immunity.Nat Rev Immunol2015https://conductscience.org/library/papers/26027717PubMed
1527912061Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.Cell2016https://conductscience.org/library/papers/27912061PubMed
1616585541CD8 T cells specific for lymphocytic choriomeningitis virus require type I IFN receptor for clonal expansion.J Immunol2006https://conductscience.org/library/papers/16585541PubMed
1715814665Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation.J Immunol2005https://conductscience.org/library/papers/15814665PubMed
1821108462Effects of IFN-α as a signal-3 cytokine on human naïve and antigen-experienced CD8(+) T cells.Eur J Immunol2010https://conductscience.org/library/papers/21108462PubMed
1928196594Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment.Cancer Cell2017https://conductscience.org/library/papers/28196594PubMed
2023045272Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses.Oncogene2013https://conductscience.org/library/papers/23045272PubMed

See all 50 referencesDownload CSV of references

Cited by34

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 49 citations.

PMIDTitleJournalYearIn PapersSource
42981393IFNAR1 stabilization sustains CD8+ T cell persistence in IFN-high colorectal cancer liver metastases.Sci Adv2026https://conductscience.org/library/papers/42981393PubMed
42760581Co-stimulatory signal deficiency impairs cytotoxic T lymphocyte function in tumor immune evasion: molecular mechanisms and therapeutic implications.J Transl Med2026https://conductscience.org/library/papers/42760581PubMed
42128668Cross-species transcriptomic integration reveals a MIRO1-mediated macrophage-T cell axis in glioma.Life Sci Alliance2026https://conductscience.org/library/papers/42128668PubMed
41930181Roles of ADP-Ribosyltransferases in Cancer.Oncol Res2026https://conductscience.org/library/papers/41930181PubMed
41463260Targeting MARylation and DePARylation in Cancer Therapy: New Promising Therapeutic Opportunities.Cancers (Basel)2025https://conductscience.org/library/papers/41463260PubMed
41059489The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances.MedComm (2020)2025https://conductscience.org/library/papers/41059489PubMed
40904702PARP (Poly ADP-ribose Polymerase) Family in Health and Disease.MedComm (2020)2025https://conductscience.org/library/papers/40904702PubMed
40741921Mono-ADP-ribosylating PARP enzymes in cellular signaling and disease.J Cell Sci2025https://conductscience.org/library/papers/40741921PubMed
40341026Development and optimization of Eva1 (MPZL2) targeting chimeric antigen receptor T cells.J Immunother Cancer2025https://conductscience.org/library/papers/40341026PubMed
40297580Immunocytes in the tumor microenvironment: recent updates and interconnections.Front Immunol2025https://conductscience.org/library/papers/40297580PubMed
40046061Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond.Front Immunol2025https://conductscience.org/library/papers/40046061PubMed
40017131Tumor‑associated neutrophils: Critical regulators in cancer progression and therapeutic resistance (Review).Int J Oncol2025https://conductscience.org/library/papers/40017131PubMed
39949782Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.Front Immunol2025https://conductscience.org/library/papers/39949782PubMed
39189367PARP enzymes and mono-ADP-ribosylation: advancing the connection from interferon-signalling to cancer biology.Expert Rev Mol Med2024https://conductscience.org/library/papers/39189367PubMed
39167664Modified C-type natriuretic peptide normalizes tumor vasculature, reinvigorates antitumor immunity, and improves solid tumor therapies.Sci Transl Med2024https://conductscience.org/library/papers/39167664PubMed
39066732Pathological and physiological roles of ADP-ribosylation: established functions and new insights.Biol Chem2024https://conductscience.org/library/papers/39066732PubMed
39062190Expanding the Perspective on PARP1 and Its Inhibitors in Cancer Therapy: From DNA Damage Repair to Immunomodulation.Biomedicines2024https://conductscience.org/library/papers/39062190PubMed
39019005PARP11 inhibition inactivates tumor-infiltrating regulatory T cells and improves the efficacy of immunotherapies.Cell Rep Med2024https://conductscience.org/library/papers/39019005PubMed
38754421ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity.Cell2024https://conductscience.org/library/papers/38754421PubMed
38402224The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.Nat Commun2024https://conductscience.org/library/papers/38402224PubMed

See all 34 cited byDownload CSV of cited by

Genes16

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35637402

GET https://conductscience.org/api/papers/v1/35637402/authors?page=2